PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-3.88%
Cash & equivalents declining -3.88% while RVPH's grows 19.42%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-3.88%
Below half of RVPH's 19.42%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.86%
Other current assets growth < half of RVPH's -30.60%. David Dodd sees a leaner approach to short-term items.
-4.12%
Below half of RVPH's 16.46%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-3.46%
Both RVPH and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Non-Current Assets Growth compared to RVPH's zero value, indicating worse performance.
-3.14%
Both RVPH and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
-4.09%
Below half of RVPH's 16.46%. Michael Burry sees a potential red flag for stagnation or capital shortage.
36.45%
Less than half of RVPH's -8.05%. David Dodd sees a more disciplined AP approach or lower volume.
25.40%
Higher Short-Term Debt Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-55.39%
Both RVPH and the company show zero Deferred Revenue (Current) Growth.
-25.40%
50-75% of RVPH's -36.18%. Bruce Berkowitz notes a more controlled liability line.
32.92%
Less than half of RVPH's -20.14%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.34%
Higher Total Non-Current Liabilities Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
4.45%
Less than half of RVPH's -19.67%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.53%
0.75-0.9x RVPH's -4.42%. Bill Ackman questions if competitor reinvests profits more robustly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.86%
Below half RVPH's 26.77%. Michael Burry sees potential underperformance in building shareholder capital.
-4.09%
Below half RVPH's 16.46%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-1.77%
Higher Total Debt Growth compared to RVPH's zero value, indicating worse performance.
3.93%
Less than half of RVPH's -19.42%. David Dodd sees better deleveraging or stronger cash buildup than competitor.